MEDICINOVA, INC. Files 8-K for Material Definitive Agreement

Ticker: MNOV · Form: 8-K · Filed: Dec 30, 2025 · CIK: 1226616

Medicinova INC 8-K Filing Summary
FieldDetail
CompanyMedicinova INC (MNOV)
Form Type8-K
Filed DateDec 30, 2025
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$0.001, $50,000,000, $75,000
Sentimentneutral

Sentiment: neutral

Topics: material-definitive-agreement, filing

TL;DR

Medicinova signed a big deal, filing an 8-K on 12/29/25.

AI Summary

On December 29, 2025, MEDICINOVA, INC. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in La Jolla, CA, filed this 8-K report to disclose this event. The filing also includes financial statements and exhibits.

Why It Matters

This filing indicates a significant new contract or partnership for Medicinova, which could impact its future business operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to the terms, execution, and potential impact on the company's financial health.

Key Numbers

Key Players & Entities

FAQ

What type of material definitive agreement did Medicinova, Inc. enter into?

The filing indicates Medicinova, Inc. entered into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing was on December 29, 2025.

Where are Medicinova, Inc.'s principal executive offices located?

Medicinova, Inc.'s principal executive offices are located at 4275 Executive Square, Suite 300, La Jolla, CA 92037.

What is Medicinova, Inc.'s state of incorporation?

Medicinova, Inc. is incorporated in Delaware.

What is the SEC file number for Medicinova, Inc.?

The SEC file number for Medicinova, Inc. is 001-33185.

Filing Stats: 886 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2025-12-30 07:53:12

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Equity Distribution Agreement by and between the Company and Lucid Capital Markets, LLC, dated December 29, 2025. 5.1 Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP. 23.1 Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MEDICINOVA, INC. By: /s/ Yuichi Iwaki, M.D., Ph.D. Name: Yuichi Iwaki, M.D., Ph.D. Title: President and Chief Executive Officer Dated: December 29, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing